Long term administration of granulocyte-macrophage colony stimulating factor decreases development of 1-2 dimethylhydrazine-induced colon cancer in rats

Journal of Surgical Oncology

Volumn 95, Issue 1, 2007, Pages 12-21

  Dinc, Soykan ^a   Ozbirecikli, Bulent ^a   Kuru, Bekir ^a   Gulcelik, Mehmet Ali ^a   Ustun, Huseyin ^b   Alagol, Haluk ^a   Oz, Murat ^c  

^a Oncology Training and Research Hospital ^*  (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Colon cancer; Dimethylhydrazine; Free radicals; Granulocyte macrophage colony stimulating factor; Nitric oxide

Indexed keywords

1,2 DIMETHYLHYDRAZINE; FREE RADICAL; GLUTATHIONE PEROXIDASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MALONALDEHYDE; NITRATE; NITRIC OXIDE; NITRITE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INHIBITION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOMODULATION; LONG TERM CARE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; COLONIC NEOPLASMS; FREE RADICALS; GLUTATHIONE PEROXIDASE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LIPID PEROXIDATION; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 33846335506     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20540     Document Type: Article

References (51)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al.: Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Potter JD: Colorectal cancer: Molecules and populations. J Natl Cancer Inst 1999;91:916-932.
3. Lau AS, Lehman D, Geertsma FR, et al.: Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons. Pediatr Infect Dis J 1996;15:563-575.
4. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
5. Grabstein KH, Urdal DL, Tushinski RJ, et al.: Induction of macrophage tumouricidal activity by Granulocyte macrophage colony stimulating factor. Science 1986;232:506-508.
6. Calatayud S, Warner TD, Breese EJ, et al.: Modulation by colony stimulating factors of human epithelial colon cancer cell apoptosis. Cytokine 2002;20:163-167.
7. Natori T, Sata M, Washida M, et al.: G-CSF stimulates angiogenesis and promotes tumor growth: Potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun 2002;297:1058-1061.
8. Hill AD, Redmond HP, Austin OM, et al.: Granulocyte-macrophage colony-stimulating factor inhibits tumour growth. Br J Surg 1993;80:1543-1546.
9. Dranoff G, Jaffee E, Lazenby A, et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
10. Ragnhammar P: Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors. Med Oncol 1996;13:167-176.
11. Hill AD, Redmond HP, Naama HA, et al.: Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Surgery 1996;119:178-185.
12. Druckrey H, Preussmann R, Matzkies F, et al.: Selektive erzeugung von darmkrebs bei ratten durch 1,2-dimethyl-hydrazin. Naturwissenschaften 1967;54:285-286.
13. Nigro ND, Bhadrachari N, Chomchai C: A rat model for studying colonic cancer. Dis Colon Rec 1973;16:438-441.
14. Gilbert JM: Experimental colorectal cancer as a model of human disease. Ann R Coll Surg Engl 1987;69:48-53.
15. Pozharisski KM, Likhachev AJ, Klimashevski VF, et al.: Experimental intestinal cancer research with special reference to human pathology. Adv Cancer Res 1979;30:165-237.
16. Dethlefsen LA, Prewitt JM, Mendelsohn ML: Analysis of tumor growth curves. J Natl Cancer Inst 1968;40:389-405.
17. Dinc S, Ozaslan C, Kuru B, et al.: Methylene blue prevents surgery-induced peritoneal adhesions but impairs early phase of anastomotic wound healing. Can J Surg 2006 (in press).
18. Qureshi A, Gorey TF, Byrne P, et al.: Oxygen free radical activity in experimental colonic carcinoma. Br J Surg 1994;81:1058-1059.
19. Moghadasian MH, Freeman HJ, Godin DV: Endogenous antioxidant status in neoplastic and adjacent tissues in 1,2-dimethylhydrazine-induced colon cancer in rats: Effects of olsalazine. Carcinogenesis 1996;17:983-987.
20. Babbs CF: Free radicals and the etiology of colon cancer. Free Radic Biol Med 1990;8:191-200.
21. Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer 2003;3:276-285.
22. Payne CM, Bernstein C, Bernstein H, et al.: Reactive nitrogen species in colon carcinogenesis. Antioxid Redox Signal 1999;1:449-467.
23. Goodman JE, Hofseth LJ, Hussain SP, et al.: Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 2004;44:3-9.
24. Rao CV: Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004;555:107-119.
25. Soiffer R, Lynch T, Mihm M, et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141-13146.
26. Dranoff G: GM-CSF-based cancer vaccines. Immunol Rev 2002;188:147-154.
27. Enzler T, Gillessen S, Manis JP, et al.: Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 2003;197:1213-1219.
28. Robin G, Markovich S, Athamna A, et al.: Human recombinant granulocyte-macrophage colony-stimulating factor augments viability and cytotoxic activities of human monocyte-derived macrophages in long-term cultures. Lymphokine Cytokine Res 1991;10:257-263.
29. Blanchard DK, Djeu JY: Differential modulation of surface antigens on human macrophages by IFN-gamma and GM-CSF: Effect on susceptibility to LAK lysis. J Leukoc Biol 1991;50:28-34.
30. Armitage JO: Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998;92:4491-4508.
31. Arnaout MA, Wang EA, Clark SC, et al.: Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986;78:597-601.
32. Morrissey PJ, Bressler L, Park LS, et al.: Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987;139:1113-1119.
33. Mach N, Gillessen S, Wilson SB, et al.: Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-3246.
34. Kuratko C, Pence BC: Rat colonic antioxidant status: Interaction of dietary fats with 1,2-dimethylhydrazine challenge. J Nutr 1992;122:278-282.
35. Skrzydlewska E, Sulkowski S, Koda M, et al.: Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol 2005;11:403-406.
36. Keshavarzian A, Zapeda D, List T, et al.: High levels of reactive oxygen metabolites in colon cancer tissue: Analysis by chemiluminescence probe. Nutr Cancer 1992;17:243-249.
37. Keshavarzian A, Olyaee M, Sontag S, et al.: Increased levels of luminol-enhanced chemiluminescence by rectal mucosa of patients with colonic neoplasia: A possible marker for colonic neoplasia. Nutr Cancer 1993;19:201-206.
38. Ambs S, Bennett WP, Merriam WG, et al.: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999;91:86-88.
39. Haklar G, Sayin-Ozveri E, Yuksel M, et al.: Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors. Cancer Lett 2001;165:219-224.
40. Hazar B, Polat G, Bagdatoglu O, et al.: The role of fibronectin and nitric oxide (NO) in gastrointestinal cancers. Hepatogastroenterology 2005;52:119-122.
41. Hofseth LJ, Saito S, Hussain SP, et al.: Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003;100:143-148.
42. Arabs S, Merriam WG, Ogunfusika MO, et al.: p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998;4:1371-1376.
43. Morbidelli L, Donnini S, Ziche M: Role of nitric oxide in the modulation of angiogenesis. Curr Pharm Des 2003;9:521-530.
44. Tomasi A, Albano E, Botti B, et al.: Detection of free radical intermediates in the oxidative metabolism of carcinogenic hydrazine derivatives. Toxicol Pathol 1987;15:178-183.
45. Noda A, Noda H, Ohno K, et al.: Spin trapping of a free radical intermediate formed during microsomal metabolism of hydrazine. Biochem Biophys Res Commun 1985;133:1086-1091.
46. Kalyanaraman B, Sinha BK: Free radical-mediated activation of hydrazine derivatives. Environ Health Perspect 1985;64:179-184.
47. Ben-Hur H, Gurevich P, Zion H, et al.: Immune response of rat spleen cells to a carcinogen and to vaccination with anti-p53 polyclonal antibodies. Anticancer Res 1998;18:273-2781.
48. Spinardi-Barbisan AL, Kaneno R, Barbisan LF, et al.: Chemically induced immunotoxicity in a medium-term multiorgan bioassay for carcinogenesis with Wistar rats. Toxicol Appl Pharmacol 2004;194:132-140.
49. Mikhailowski R, Shpitz B, Polak-Charcon S, et al.: Controlled release of TGF-beta1 impedes rat colon carcinogenesis in vivo. Int J Cancer 1998;78:618-623.
50. Hone H, Kanazawa K, Kobayashi E, et al.: Effects of intestinal bacteria on the development of colonic neoplasm II. Changes in the immunological environment Eur J Cancer Prev 1999;8:533-537.
51. Oliveira EC, Leite MS, Miranda JA, et al.: Chronic Trypanosoma cruzi infection associated with low incidence of 1,2-dimethylhydrazine-induced colon cancer in rats. Carcinogenesis 2001;22:737-740.